Vivus beats the street on licensing payments, but investors aren't fooled

Vivus ($VVUS), a go-it-alone marketer with flailing obesity drug Qsymia, is discovering the joys of buddying up. Licensing revenue from agreements for erectile dysfunction drug Stendra cut the company's losses to $0.17 per share, a 70% improvement. But investors looked past licensing revenue to still-flimsy Qsymia sales, which sent shares down by close to 13% in premarket trading Tuesday. More